top of page
Kanglin Biotec
Clinical Trial Results
X003 has demonstrated exceptional results in clinical trials for beta-thalassemia patients.
94.1%
of patients achieved transfusion independence, meaning they no longer needed regular blood transfusions after treatment.
Since Q3 2025, over 50 patients have been treated with X003 in real-world settings. The treatment has shown similar success rates outside of clinical trials, ensuring that X003 is not just effective in controlled environments but also in real, everyday scenarios.
50+
bottom of page